Presenting combinatorial ex vivo evaluation of 3D patient-derived organoids in colorectal cancer

SINGAPORE, November 14, 2023 /EINPresswire.com/ -- KYAN Technologies, a clinical-stage, functional precision medicine company, today announced a poster presentation at the 2023 AACR-KCA Joint Conference on Precision Medicine in Cancer to be held in Seoul, Korea from November 15-17, 2023.

Details related to the poster presentation:

Poster Number: P2-062

Abstract Number: AK23_00594

Abstract Title: Harnessing Optim.AI™ and PD3D^® models to investigate combinatorial therapies involving MAPK pathway inhibition in colorectal cancer

Session: Poster Session 2 (Friday, November 17th, 2023 from 08:30-17:20 KST)

Place: Lotte Hotel Seoul, Emerald Room (2F)


About KYAN Technologies

KYAN Technologies Pte Ltd is a leader in the field of functional precision medicine, committed to addressing unmet needs and gaps in cancer treatment through small data AI and the phenotypic perturbation of biological models including patient samples and organoids. KYAN Technologies’ flagship platform, Optim.AI™, has been applied in clinical studies for non-hodgkin lymphoma, acute myeloid leukemia and soft tissue sarcomas, producing clinical benefit results and insights on novel therapeutic combinations that could improve patient outcomes, particularly for relapsed, refractory and rare cancers. KYAN Technologies has been licensed by the Singapore Ministry of Health as a clinical laboratory.

Sudha Sruthi
KYAN Technologies Pte Ltd
ssruthi@kyantechnologies.com
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.